CLINICAL LUNG CANCER AUTHOR INFORMATION PACK TABLE OF CONTENTS XXX . • Description p.1 • Impact Factor p.1 • Abstracting and Indexing p.1 • Editorial Board p.1 • Guide for Authors p.4 ISSN: 1525-7304 DESCRIPTION . Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches. Benefits to authors We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services. Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center IMPACT FACTOR . 2020: 4.785 © Clarivate Analytics Journal Citation Reports 2021 ABSTRACTING AND INDEXING . Scopus Embase CINAHL Chemical Abstracts Ovid EBSCOhost PubMed/Medline EDITORIAL BOARD . Editor-in-Chief Antoinette Wozniak, Pittsburgh, Pennsylvania, United States of America AUTHOR INFORMATION PACK 27 Sep 2021 www.elsevier.com/locate/jclc 1 Senior Associate Editors Shirish Gadgeel, Henry Ford Cancer Institute - Henry Ford Hospital, Department of Internal Medicine, Detroit, Michigan, United States of America Laurie Gaspar, University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States of America Balazs Halmos, Montefiore Medical Center, Bronx, New York, United States of America Friedrich Knollmann, Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States of America Jonathan Riess, University of California Davis School of Medicine, Sacramento, California, United States of America Inderpal (Netu) S. Sarkaria, University of Pittsburgh Department of Cardiothoracic Surgery, Pittsburgh, Pennsylvania, United States of America Associate Editors David T. Cooke, University of California Davis Health System, Sacramento, California, United States of America Walter J. Curran Jr., Emory University School of Medicine, Philadelphia, Pennsylvania, Georgia, United States of America Corey J. Langer, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States of America Tony S. Mok, The Chinese University of Hong Kong Department of Clinical Oncology, Hong Kong, Hong Kong, China Mary Redman, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America Giorgio V. Scagliotti, University of Turin, Torino, Italy Publisher Angela Carmona, Philadelphia, Pennsylvania, United States of America Editorial Board Alex A. Adjei, Mayo Clinic Rochester, Buffalo, New York, Minnesota, United States of America Area of expertise - Medical oncology, Clinical pharmacology, Drug development, Translational research Arya Amini, City of Hope Comprehensive Cancer Center Duarte, Duarte, California, United States of America Radiation Oncology Paul Baas, Antoni van Leeuwenhoek Netherlands Cancer Institute, Amsterdam, Netherlands Development of new therapies and the treatment of lung cancer and malignant mesothelioma Paolo Bironzo, University of Turin, Torino, Italy Immunotherapy and solid tumors Collin Blakely, University of California San Francisco, San Francisco, California, United States of America Medical Oncology; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Michael Boyer, Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia Conjoint Chair of Medical Oncology (Thoracic Oncology); new anticancer drugs for the treatment of lung cancer Elisabeth Brambilla, University Grenoble Alpes, Grenoble, France lung tumor pathology Paul A. Bunn, University of Colorado, Aurora, Colorado, USA Translational research in lung cancer; identifying novel diagnostics and treatment strategies Timothy Burns, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States of America Medical Oncology; KRAS mutant non-small cell lung cancer; EGFR mutant lung cancer Brett Carter, University of Texas MD Anderson Cancer Center, Department of Gastroenterology, Hepatology and Nutrition, Houston, Texas, United States of America Imaging; Diagnostic Imaging; Interventional Radiology Wei Chen, Wayne State University, Detroit, Michigan, United States of America Sanja Dacic, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States of America Pathology Suzanne Dahlberg, Harvard Medical School, Boston, Massachusetts, United States of America Biostatistics & Computational Biology Justin Gainor, Harvard Medical School, Boston, Massachusetts, USA Design of clinical trials evaluating novel therapeutics for molecularly-defined subsets of non-small cell lung cancer; translational research Giuseppe Giaccone, Georgetown University, Georgetown, Maryland, District of Columbia, United States of America Developmental therapeutics; thymoma Glenwood Goss, Ottawa Hospital, Ottawa, Ontario, Canada Early cancer drug development and thoracic oncology Koichi Goto, National Cancer Center Higashi Hospital, Chiba, Japan Primary lung cancer, mediastinal tumors, and pleural tumors John Heymach, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America AUTHOR INFORMATION PACK 27 Sep 2021 www.elsevier.com/locate/jclc 2 Molecular drivers of lung cancer, identification of predictive biomarkers of drug sensitivity, and identification of mechanisms of therapeutic resistance and novel strategies to overcome resistance Fred Hirsch, University of Colorado Denver, Denver, Colorado, United States of America Steven Kao, Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia Niki Karachaliou, Sacred Heart Hospital, Barcelona, Spain Medical Oncology; Translational Research Edward Kim, Levine Cancer Institute, Charlotte, North Carolina, United States of America Chair of the Department of Solid Tumor Oncology; thoracic cancer and cancers of the head and neck; molecular prognostication for lung cancer Feng-Ming (Spring) Kong, Case Western Reserve University, Cleveland, Ohio, United States of America Radiation Oncology Zhang Li, Sun Yat-Sen University, Guangzhou, China Clinical trials in lung cancer, new therapeutics, molecular markers Philip Mack, University of California Davis Medical Center, Davis, California, United States of America Molecular biology and molecular pharmacology studies; basic and translational research; molecular and cellular effects of novel anticancer agents Christian Manegold, University Medical Centre Mannheim Department of Surgery, Mannheim, Germany Surgery Daniel Morgensztern, Washington University in St Louis School of Medicine, Saint Louis, Missouri, United States of America Medical Oncology; Thoracic malignancies Sai-Hong Ignatius Ou, University of California Irvine, Irvine, California, United States of America Area of expertise - Nasopharyngeal Carcinoma, Head and Neck Cancer, Thoracic malignancies, Esophageal carcinoma, Targeted therapy David Planchard, Gustave Roussy Department of Oncological Medicine, Villejuif, France Genomic analysis (and high-throughput technologies) to drive lunch cancer patients to specific targeted agents Suresh Ramalingam, Emory University School of Medicine, Atlanta, Georgia, United States of America Immune checkpoint inhibitors and improving outcomes for patients with EGFR mutation Karen Reckamp, Cedars-Sinai Medical Center, Los Angeles, California, United States of America Jordi Remon, HM Delfos, Barcelona, Spain Medical Oncology; genomic characterization by liquid biopsies, as well as, the improvement in therapeutic strategies in thymic malignancies and mechanisms of resistance in small cell lung cancers Jill Siegfried, University of Pittsburgh, Rochester, Minnesota, Pennsylvania, United States of America Pharmacology; lung cancer biology and experimental therapeutics, focusing on targeting growth factors and hormone signaling that control lung cancer cell proliferation to treat lung cancer, and how immunotherapy can be enhanced by targeted therapy Thomas Stinchcombe, Duke University School of Medicine, Durham, North Carolina, United States of America Clinical care, clinical trials, and developing new therapies; Medical Oncology Kenichi Suda, Kindai University ,Faculty of Medicine, Division of Thoracic Surgery, Department of Surgery, Osaka, Japan EGFR mutation; Acquired resistance; Neoadjuvant therapy; Molecular target; Thoracic surgery Stephen Swisher, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America Thoracic and Cardiovascular Surgery Masahiro Tsuboi, Tokyo Medical University, Shinjuku-Ku, Japan Thoracic Surgery Liza Villaruz, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States of America Medical Oncology; lung cancer and thoracic malignancies Jie Wang, Peking University, Beijing, China Clinical trials in lung cancer, new therapeutics, molecular markers Maria Werner-Wasik, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States of America Radiation Yi-Long Wu, Guangdong Provincial People's Hospital, Guangzhou, China Multidisciplinary therapy and translational medicine